In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

(2015) Paula L. McClean et al.   BEHAVIOURAL BRAIN RESEARCH

Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide™

(2015) Patricia Kelly et al.   MICROCIRCULATION

GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration

(2015) Ethan A Winkler et al.   NATURE NEUROSCIENCE

Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging

(2014) Grazia D. Femminella et al.   Alzheimers & Dementia

At the Centennial of Michaelis and Menten, Competing Michaelis-Menten Steps Explain Effect of GLP-1 on Blood-Brain Transfer and Metabolism of Glucose

(2014) Michael Gejl et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Cerebral Blood Flow is an Earlier Indicator of Perfusion Abnormalities than Cerebral Blood Volume in Alzheimer's Disease

(2014) María Lacalle-Aurioles et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

New drug treatments show neuroprotective effects in Alzheimer′s and Parkinson′s diseases

(2014) Christian Hölscher   Neural Regeneration Research

Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

(2013) Jessica Freiherr et al.   CNS DRUGS

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

(2013) Paula L. McClean et al.   NEUROPHARMACOLOGY

Washout allometric reference method (WARM) for parametric analysis of [11C]PIB in human brains

(2013) Anders Rodell et al.   Frontiers in Aging Neuroscience

The diabetes drug liraglutide ameliorates insulin resistance in the hippocampal formation of Alzheimer's disease (AD) cases

(2012) Konrad Talbot et al.   Alzheimers & Dementia

Increased Cerebral Metabolism After 1 Year of Deep Brain Stimulation in Alzheimer Disease

(2012) Gwenn S. Smith et al.   ARCHIVES OF NEUROLOGY

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

(2012) Kerry Hunter et al.   BMC NEUROSCIENCE

Glucagon-Like Peptide-1 Decreases Intracerebral Glucose Content by Activating Hexokinase and Changing Glucose Clearance during Hyperglycemia

(2012) Michael Gejl et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

(2012) Theresa R. Bomfim et al.   JOURNAL OF CLINICAL INVESTIGATION

Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment

(2011) Suzanne Craft   ARCHIVES OF NEUROLOGY

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial

(2010) Philip Scheltens et al.   Alzheimers & Dementia

The use of PET in Alzheimer disease

(2010) Agneta Nordberg et al.   Nature Reviews Neurology

Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease

(2010) Ahmadul Kadir et al.   NEUROBIOLOGY OF AGING

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

(2009) J. Jendle et al.   DIABETES OBESITY & METABOLISM

Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study

(2009) W. L. Xu et al.   DIABETOLOGIA

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

(2009) Paula L. McClean et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Assessment of β-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11–Labeled Pittsburgh Compound B

(2008) Ville Leinonen   ARCHIVES OF NEUROLOGY